Search Results - "Lubomír, Minařík"

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents by Bašová, Petra, Paszeková, Helena, Minařík, Lubomír, Dluhošová, Martina, Burda, Pavel, Stopka, Tomáš

“…The transcription factor PU.1 (Purine-rich DNA binding, SPI1) is a key regulator of hematopoiesis, whose level is influenced by transcription through its…”
Get full text

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial by Stopka, Tomáš, Minařík, Lubomír, Dusilková, Nina, Pešta, Michal, Kulvait, Vojtěch, Špaček, Martin, Zemanová, Zuzana, Kalousová, Marta, Jonášová, Anna

“…Trial registration GA trial is registered under EudraCT#: 2013-001639-38…”
Get full text

P692: THE KEAP1‐NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5‐AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS by Pimková, Kristýna, Minařík, Lubomír, Myšáková, Michaela, Kokavec, Juraj, Stopka, Tomáš

Get full text

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways by Minařík, Lubomír, Pimková, Kristýna, Kokavec, Juraj, Schaffartziková, Adéla, Vellieux, Fréderic, Kulvait, Vojtěch, Daumová, Lenka, Dusilková, Nina, Jonášová, Anna, Vargová, Karina Savvulidi, Králová Viziová, Petra, Sedláček, Radislav, Zemanová, Zuzana, Stopka, Tomáš

“…The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive…”
Get full text

The role of the KEAP1-NRF2 antioxidant pathway in the cell response to anti-leukemic therapy by Michaela, Myšáková, Kristýna, Pimková, Lubomír, Minařík, Tomáš, Stopka

Get full text

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa by Jonasova, Anna, Sotakova, Slavka, Belohlavkova, Petra, Minarik, Lubomir, Stopka, Tomas, Jonas, Jan Jakub, Aghova, Tatiana, Zemanova, Zuzana

“…Luspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic…”
Get full text

Re-Sensitization of Azacytidine-Resistant MDS/AML Cells Via Modulation of KEAP1-NRF2 Redox Pathway by Pimkova, Kristyna, Minařík, Lubomir, Kokavec, Juraj, Stopka, Tomas

Get full text

First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy by Jonasova, Anna, Minarik, Lubomir, Zemanova, Zuzana, Polackova, Helena, Stopka, Tomas

Get full text

NQO 12 polymorphism predicts overall survival in MDS patients by Moudra, Alena, Minarik, Lubomir, Vancurova, Marketa, Bartek, Jiri, Hodny, Zdenek, Jonasova, Anna

Get full text

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis by Jonasova, Anna, Minarik, Lubomir, Kulvait, Vojtech, Pesta, Michal, Schaffartzikova, Adel, Kislik, Galina, Dusilkova, Nina, Zemanova, Zuzana, Stopka, Tomas

“…Introduction: Myelodysplastic syndrome (MDS) is characterized by differentiation blockade, cytopenias with commontransfusion dependency and immune defects…”
Get full text

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome by Polgarova, Kamila, Kulvait, Vojtech, Vargova, Karina, Minarik, Lubomir, Dusilkova, Nina, Zemanova, Zuzana, Jonasova, Anna, Stopka, Tomas

“…Introduction: Myelodysplastic syndromes (MDS) are clonal disorders of myeloid hematopoietic stem cells. Recent studies has shown that nearly 90% of patients…”
Get full text

NQO12 polymorphism predicts overall survival in MDS patients by Moudra, Alena, Minarik, Lubomir, Vancurova, Marketa, Bartek, Jiri, Hodny, Zdenek, Jonasova, Anna

Get full text

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders by Polgarova, Kamila, Vargova, Karina, Kulvait, Vojtech, Dusilkova, Nina, Minarik, Lubomir, Zemanova, Zuzana, Pesta, Michal, Jonasova, Anna, Stopka, Tomas

“…Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized…”
Get full text

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System by Minarik, Lubomir, Drusbosky, Leylah M., Abbasi, Taher, Vargova, Karina, Kulvait, Vojtech, Jonasova, Anna, Singh, Neeraj Kumar, Ullal, Yashaswini S, Narayanabhatia, Sirisha, Alam, Aktar, Roy, Kunal Ghosh, Choudhary, Ashish, Vali, Shireen, Cogle, Christopher R., Stopka, Tomas

“…BACKGROUND: Azacitidine (AZA) is currently a drug of choice for most of high-risk MDS patients. However, only 40-50% of MDS patients achieve clinical…”
Get full text

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options by Minarik, Lubomir, Drusbosky, Leylah M., Abbasi, Taher, Vargova, Karina, Kulvait, Vojtech, Jonasova, Anna, Singh, Neeraj Kumar, Kumar, Chandan, Suseela, Rakhi Purushothaman, Patil, Mamatha, Dattatraya, Patil Nilesh, Tiwari, Krishna Kumar, Vali, Shireen, Cogle, Christopher R., Stopka, Tomas

“…BACKGROUND:TET2 (Ten-eleven-translocation-2) mutations found in 10-30% of MDS and AML patients are actionable for Azacitidine (AZA) treatment (PMID: 21828143)…”
Get full text

Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients) by Jonasova, Anna, Neuwirtova, Radana, Polackova, Helena, Siskova, Magda, Stopka, Tomas, Cmunt, Eduard, Belickova, Monika, Moudra, Alena, Minarik, Lubomir, Fuchs, Ota, Michalova, Kyra, Zemanova, Zuzana

“…•Lenalidomide is highly effective in low risk myelodysplastic syndrome with del(5q).•Borderline bone marrow blasts and TP53 mutation signal a risk of…”
Get full text